Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial

Kjeldsen, Sverre E, Julius, Stevo, Mancia, Giuseppe, McInnes, Gordon T, Hua, Tsushung, Weber, Michael A, Coca, Antonio, Ekman, Steffan, Girerd, Xavier, Jamerson, Kenneth, Larochelle, Pierre, MacDonald, Thomas M, Schmieder, Roland E, Schork, M Anthony, Stolt, Pelle, Viskoper, Reuven, Widimský, Jiri, Zanchetti, Alberto·2006·Journal of Hypertension

Abstract

CONTEXT: Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease. OBJECTIVE: To test for the first time the hypothesis that treatment of hypertensive patients at high cardiovascular risk with the angiotensin-receptor blocker (ARB) valsartan prevents new-onset type 2 diabetes compared with the metabolically neutral calcium-channel antagonist (CCA) amlodipine. DESIGN: Pre-specified analysis in the VALUE trial. Follow-up averaged 4.2 years. The risk of developing new diabetes was calculated as an odds ratio (OR) with 95% confidence intervals (CI) for different definitions of diabetes. PATIENTS: A sample of 9995 high-risk, non-diabetic hypertensive patients. INTERVENTIONS: Valsartan or amlodipine with or without add-on medication [hydrochlorothiazide (HCTZ) and other add-ons, excluding other ARBs, angiotensin-converting enzyme (ACE) inhibitors, CCAs]. MAIN OUTCOME MEASURE: New diabetes defined as an adverse event, new blood-glucose-lowering drugs and/or fasting glucose > 7.0 mmol/l. RESULTS: New diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine (OR 0.77, 95% CI 0.69-0.87, P < 0.0001). Using stricter criteria (without adverse event reports) new diabetes was detected in 495 (9.8%) patients on valsartan and in 586 (11.8%) on amlodipine (OR 0.82, 95% CI 0.72-0.93, P = 0.0015). CONCLUSION: Compared with amlodipine, valsartan reduces the risk of developing diabetes mellitus in high-risk hypertensive patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.hjh.0000234122.55895.5b

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 160

Metadata

Authors
Kjeldsen, S. E., Julius, S., Mancia, G., McInnes, G. T., Hua, T., Weber, M. A., Coca, A., Ekman, S., Girerd, X., Jamerson, K., Larochelle, P., MacDonald, T. M., Schmieder, R. E., Schork, M. A., Stolt, P., Viskoper, R., Widimský, J., & Zanchetti, A.
Venue
Journal of Hypertension
Published
2006-07
Volume
24
Issue
7
Pages
1405-1412
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2166263247
Cited by
160
References
7
FWCI
17.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. https://app.cochat.ai/papers/10.1097/01.hjh.0000234122.55895.5b
The paper
Kjeldsen, S. E., Julius, S., Mancia, G., McInnes, G. T., Hua, T., Weber, M. A., Coca, A., Ekman, S., Girerd, X., Jamerson, K., Larochelle, P., MacDonald, T. M., Schmieder, R. E., Schork, M. A., Stolt, P., Viskoper, R., Widimský, J., & Zanchetti, A. (2006). Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension. https://doi.org/10.1097/01.hjh.0000234122.55895.5b

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.